Your browser doesn't support javascript.
loading
[Side Effect Management in the Early Stages of Cabozantinib Administration].
Gan To Kagaku Ryoho ; 48(10): 1269-1271, 2021 Oct.
Article in Ja | MEDLINE | ID: mdl-34657061
ABSTRACT
In 2 patients with postoperative lung metastases from renal cell carcinoma, we administered cabozantinib at a starting dose of 40 mg. The side effects were proteinuria(Grade 2), hand-foot syndrome(Grade 2), and hypertension(Grade 3), which subsided following dose reduction and drug suspension. We believe that a low starting dose of cabozantinib might be a suitable regimen for advanced renal cell carcinoma.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms / Antineoplastic Agents Limits: Humans Language: Ja Journal: Gan To Kagaku Ryoho Year: 2021 Document type: Article
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms / Antineoplastic Agents Limits: Humans Language: Ja Journal: Gan To Kagaku Ryoho Year: 2021 Document type: Article